The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Kolesnikova L.V.
FGBU "Rostovskiĭ NII akusherstva i pediatrii" Minzdravsotsrazvitiia Rossii, Rostov-na-Donu
Ermolova N.V.
Federal State Budgetary Institution «Rostov Scientific-Research Institute of Obstetrics and Pediatrics» of the Ministry of Health of the Russia, Rostov-on-Don, Russia, 344012
Linde V.A.
Federal State Budgetary Institution «Rostov Scientific-Research Institute of Obstetrics and Pediatrics» of the Ministry of Health of the Russia, Rostov-on-Don, Russia, 344012
Markaryan I.V.
FSBI «Rostov Scientific and Research Institute of Obstetrics and Pediatrics» of the Ministry of Health of Russia, Rostov-on-Don, Russia, 344012
Avanesova T.G.
Federal State Budgetary Institution «Rostov Scientific-Research Institute of Obstetrics and Pediatrics» of the Ministry of Health of the Russia, Rostov-on-Don, Russia, 344012
The experience of Visanne use in patients of reproductive age with external genital endometriosis
Journal: Russian Journal of Human Reproduction. 2016;22(3): 101‑106
Views: 17342
Downloaded: 221
To cite this article:
Kolesnikova LV, Ermolova NV, Linde VA, Markaryan IV, Avanesova TG. The experience of Visanne use in patients of reproductive age with external genital endometriosis. Russian Journal of Human Reproduction.
2016;22(3):101‑106. (In Russ.)
https://doi.org/10.17116/repro2016223101-106
Objective - to assess the influence of endometriosis treatment with dienogest 2 mg per day on the life quality parameters. Material and methods. The study involved 74 patients of reproductive age with pain syndrome and endometriosis. The results were assessed in 3-6-12 months after the treatment (surgical and medical treatment with the dienogest). Results. Such a symptom as dysmenorrhea was treated in 100% of cases in the postoperative period in patients using Visanne. The pain syndrome disappeared in 70% of patients and in 30 and 100% there was significant relief of symptoms in 3 and 6 months respectively. No sonographic signs of disease recurrence were found in the postoperative period in 3, 6 and 12 months of treatment with dienogest. Also there was no any adverse effect of Visanne on bloodlipids and liver enzymes. Conclusions. It has been found that Visanne (dienogest) is a highly effective medicine for treatment of patients with endometriosis of different stages. It eliminate the pain syndrome and reduces the blood loss, it has a low adverse side effects rate and it has an excellent tolerability and safety, which improves the life quality of patients with endometriosis.
Authors:
Kolesnikova L.V.
FGBU "Rostovskiĭ NII akusherstva i pediatrii" Minzdravsotsrazvitiia Rossii, Rostov-na-Donu
Ermolova N.V.
Federal State Budgetary Institution «Rostov Scientific-Research Institute of Obstetrics and Pediatrics» of the Ministry of Health of the Russia, Rostov-on-Don, Russia, 344012
Linde V.A.
Federal State Budgetary Institution «Rostov Scientific-Research Institute of Obstetrics and Pediatrics» of the Ministry of Health of the Russia, Rostov-on-Don, Russia, 344012
Markaryan I.V.
FSBI «Rostov Scientific and Research Institute of Obstetrics and Pediatrics» of the Ministry of Health of Russia, Rostov-on-Don, Russia, 344012
Avanesova T.G.
Federal State Budgetary Institution «Rostov Scientific-Research Institute of Obstetrics and Pediatrics» of the Ministry of Health of the Russia, Rostov-on-Don, Russia, 344012
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.